Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?

J Glob Antimicrob Resist. 2020 Dec:23:417-419. doi: 10.1016/j.jgar.2020.10.019. Epub 2020 Nov 16.

Abstract

Objectives: We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed.

Methods: A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY, and the killing kinetics of aztreonam (ATM; 4 μg/mL), aztreonam-avibactam (ATM-AVI; 4/4 μg/mL), and colistin (2 and 4 μg/mL) were tested.

Results: ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas colistin allowed re-growth.

Conclusions: This report supports reconsideration of use of colistin for treatment of infections caused by K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps earlier than colistin.

Keywords: Aztreonam; Carbapenem-Resistant enterobacteria; Ceftazidime-Avibactam; Colistin; Klebsiella pneumonia; NDM.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds
  • Aztreonam / therapeutic use
  • Bacteremia* / drug therapy
  • Ceftazidime
  • Drug Combinations
  • Humans
  • Klebsiella Infections* / drug therapy
  • Klebsiella pneumoniae
  • Microbial Sensitivity Tests
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime
  • beta-Lactamases
  • beta-lactamase NDM-1
  • Aztreonam